China consults on healthcare reform proposals
This article was originally published in Clinica
Executive Summary
China has asked the public to comment on proposed healthcare system reforms. A 13,500-word document, written in Chinese and posted on the website of the National Development Reform Commission (shs.mdrc.gov.cn/yg), lists five priorities: hastening the establishment of a universal healthcare system (which it hopes to have in place by 2020); establishing a basic drug system; improving the grassroots health service network; to ensure equality between rural and urban healthcare provision; and speeding up the reform of government hospitals. The gap in health provision for rural and urban dwellers is cited in the document as a major cause for concern, reports China Daily. The proposal is said to recommend that large, well-equipped urban hospitals extend help to rurally-based facilities, such as by providing personnel training, technical support and “equipment assistance”.
You may also be interested in...
Asia Regulatory Forum Update
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia adopts interim device authorisation regulation
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
Canada takes action to increase more adverse event reporting
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.